Articles tagged with Amyloids
Researchers have discovered that Alzheimer's, Parkinson's, and type 2 diabetes share a common molecular mechanism, involving amyloid fibrils with a universal 'molecular zipper' structure. This finding could lead to new diagnostic tools and treatment options through 'structure-based drug design'.
A study by UC Irvine scientists found that diets rich in docosahexaenoic acid (DHA) can help prevent the development of Alzheimer's disease later in life. Mice given a DHA-rich diet showed lower levels of tau and beta amyloid, proteins associated with neurofibrillary tangles and plaques.
A study by Massachusetts General Hospital researchers found that blocking immune cell action increased amyloid-beta deposits and shortened life spans in a mouse model of Alzheimer's disease. The study suggests potential new therapeutic strategies for early-stage Alzheimer's disease.
A team led by Massachusetts General Hospital confirms that Pittsburgh Compound B binds to amyloid-beta protein in the human brain, a key step in Alzheimer's disease diagnosis. The findings support using PET imaging with PiB to track treatment results and emphasize the need for clinical symptom evaluation.
Researchers at the University of Pennsylvania found that common inhaled anesthetics increase amyloid plaque appearance and cognitive decline in genetically engineered mice. The study suggests a potential link between long-term anesthesia use and early-onset Alzheimer's disease.
A Scripps research study reveals the dynamic structural details of single prion molecules, shedding light on normal folding mechanisms and abnormal amyloid fibril conversion. The findings may lead to novel therapeutic targets for neurodegenerative diseases.
Researchers at the University of Toronto have identified a new gene, SORL1, associated with an increased risk of Alzheimer's disease in different ethnic groups. The discovery highlights the complexity of the disease's genetics and underscores the need for further replication studies.
Researchers have identified a new genetic clue that may contribute to the development of late-onset Alzheimer's disease. Variations in the SORL1 gene were found to be associated with an increased risk of the disease, and altering the levels of this protein changed the way amyloid beta fragments were produced in cells.
Researchers identified a new genetic risk factor associated with late-onset Alzheimer's, implicating the SORL1 gene. Variants of this gene are linked to an increased risk of Alzheimer's, particularly in Caucasians, and may play a role in the production of toxic amyloid-beta fragments.
Researchers discovered a genetic variation that enables adults to express higher levels of fetal hemoglobin, reducing their risk of Alzheimer's disease. The study also found that beta amyloid peptide has an affinity for adult hemoglobin, which may enhance its ability to wreak havoc in the brain.
The Biophysical Society has announced the winners of its student travel awards for their outstanding scientific contributions and presentations at the annual meeting. The recipients include Youval Ben Abou, Dovart Brass, Esther Caballero-Manrique, and other talented students recognized for their research excellence.
Researchers developed a synthetic protein fragment that blocks the interaction between Apo E and amyloid beta, reducing its aggregation by around 50% in mouse brains. The treatment showed no apparent inflammation or memory decline in animal tests.
Researchers will focus on possible therapies aimed at affecting the peptide beta amyloid and the tau protein. The consortium's work will translate basic research knowledge into clinical trials of interventions that target Alzheimer's disease mechanisms.
The three-dimensional structure of insulin-degrading enzyme suggests ways to develop drugs that could either speed up or slow down its activity. The researchers discovered small mutations that increased the enzyme's activity by 40-fold, providing a blueprint for developing similar effects.
Researchers at UCLA/VA have discovered that curcumin, a compound found in curry and turmeric, can enhance the immune system's ability to clear amyloid beta from the brain. In a study published in the Journal of Alzheimer's Disease, treated macrophages showed improved uptake of amyloid beta in 50% of patients with Alzheimer's disease.
Researchers have made significant advances in optics tests for early Alzheimer's detection, which may enable universal screening technologies. The tests can identify small molecular signs of the disease in the eye before brain pathology is present, raising hopes for early diagnosis and slowing disease progression.
Researchers found that an enzyme called Cathepsin B breaks down the amyloid plaque protein in Alzheimer's disease, offering a potential new treatment approach. Increasing CatB activity reduced plaque deposits in mice with human APP, suggesting it could be a protective mechanism against AD.
A study by Salk Institute researchers reveals that aging is a critical factor in the buildup of toxic beta amyloid aggregates in the brain. The team found that cells use an unexpected two-pronged strategy to rid themselves of these aggregates, with high molecular weight species being less toxic than smaller ones.
A recent study reveals that prion disease infectivity can cause heart damage in mice, with similarities to human amyloid heart disease. The findings have significant implications for the development of new diagnostic tests and treatments for prion diseases.
Researchers found that scyllo-inositol prevented the accumulation of amyloid â deposits, a hallmark of Alzheimer's disease, and improved cognitive abilities in mice. The study suggests that scyllo-inositol may be an effective experimental therapy for Alzheimer's disease.
The study found that soluble forms of amyloid beta are highly toxic, killing neurons in as little as 12 hours, while fibrillar forms render them useless over a period of days. Researchers hope to develop therapies targeting these different forms of amyloid beta.
OHSU researchers found that beta amyloid can be found both inside and outside of brain cell mitochondria in Alzheimer's mice, suggesting a key role in the disease. Mitochondrial oxidative damage may contribute to the progression of Alzheimer's by producing hydrogen peroxide.
Researchers at Howard Hughes Medical Institute have identified a crucial protein called TMP21 that regulates amyloid-beta production. By controlling the specific cleavage of APP, TMP21 helps keep amyloid-beta levels in check, preventing the formation of toxic plaques. This discovery may lead to new treatments for Alzheimer's disease.
A new genetic cause of Alzheimer's disease has been discovered, with increased amyloid precursor protein expression being a significant risk factor. The study found that genetic variations in the promoter region can increase gene expression and contribute to the development of Alzheimer's disease.
The landmark book celebrates the centennial of Alzheimer's discovery, narrating its evolution from a major cause of late-life dementia. The publication brings to life classic studies defining the disease research, featuring contributions from prominent researchers.
A DNA gene vaccine successfully reduced amyloid-beta 42 protein buildup in the brains of mice with a genetic mutation associated with Alzheimer's disease. The vaccine elicited high levels of antibodies and significantly decreased brain plaques, offering a promising therapeutic option for the disease.
New research reveals Pin1 enzyme plays a key role in preventing Alzheimer's disease by regulating APP cleavage and amyloid beta production. The study establishes a direct link between amyloid plaques and tau tangles, two abnormal structures associated with the disease.
A new study found that the Pin1 enzyme helps protect against age-related neurodegeneration and establishes a link between amyloid plaques and tau tangles. The researchers discovered that Pin1 regulates APP cleavage and amyloid beta production, preventing plaque formation.
Researchers discover that excessive amyloid-beta toxicity leads to functional heme deficiency, causing mitochondrial decay and oxidative damage. A new class of targeted drugs could soon be developed to address this underlying mechanism.
Researchers found that a new experimental drug, AF267B, reversed key cognitive deficits and reduced pathological plaques and tangles in the brain of Alzheimer's patients. The treatment improved learning and memory abilities in mice with amyloid plaques and neurofibrillary tangles, but not in other brain regions.
Researchers at Canadian Institutes of Health Research find that bone marrow-derived microglia can efficiently destroy amyloid plaques, the hallmark of Alzheimer's disease. The discovery provides new hope for patients by highlighting a potential therapeutic approach to curbing plaque development and prolonging autonomy.
Researchers found that increased brain cell activity drives up levels of amyloid beta, a key ingredient in Alzheimer's plaques. Corresponding drops in amyloid beta levels occurred when brain cells' ability to send messages was dampened or blocked completely.
Researchers found that resveratrol can prevent amyloid beta from killing neurons by blocking a key protein called NF-kB in microglia. This discovery singles out resveratrol as a promising therapeutic intervention for Alzheimer's disease.
The study reveals that Pme117, a glycoprotein involved in melanosomes, rapidly folds into functional amyloid fibers that enhance melanin production. This discovery suggests that amyloid formation may serve a physiological role in cells, contradicting current views on pathogenic amyloids.
Researchers have engineered mice to produce amyloid plaques in their brains, finding that treatment with drugs lowering Abeta production can prevent progression of Alzheimer's disease. However, treatment cannot reverse the disease. Early treatment with these drugs may be crucial in slowing or stopping its spread.
Researchers found that resveratrol, a compound in red wine, significantly reduces amyloid-beta peptide levels in cells. The compound is believed to stimulate the degradation of these peptides by the proteasome, a multi-protein complex. However, it remains unclear whether eating grapes can effectively prevent Alzheimer's disease.
A team of researchers used proteomics to identify multiple blood proteins that adsorb to the surfaces of medical devices, including serum amyloid P. This discovery sheds new light on the biocompatibility of materials and their potential impact on patient health.
Researchers silenced a normally functioning gene using RNA interference, reducing amyloid plaque formation and cognitive decline in mice. Within a month of treatment, impaired mice recovered memory functions.
A new dye, NIAD-4, has been developed to allow direct imaging of Alzheimer's plaques through a patient's skull without invasive procedures. The compound binds to amyloid brain plaques and fluoresces when exposed to near-infrared radiation, providing clear visual images.
Researchers discovered that a vascular gene plays a crucial role in the growth of blood vessels in brain cells. Restoring its expression level stimulates new vessel formation and improves clearance of amyloid beta peptide, a toxin associated with Alzheimer's disease.
Studies using transgenic mice reveal impaired amyloid-beta clearance leads to vascular damage and neuroinflammation in the brain. This process appears to contribute to the progression of Alzheimer's disease, suggesting novel therapeutic targets to reduce blood vessel-associated Aβ deposition.
Researchers created transgenic mice overproducing Ab40 and Ab42 to study their roles in AD pathology. The results showed that Ab42 mice accumulated extensive amyloid plaque and neural damage, while Ab40 mice showed little disease pathology. The study provides evidence for the critical role of Ab42 in initiating amyloid deposition.
Researchers discovered that macrophages in the innate immune system may play a role in Alzheimer's development. They found that healthy individuals can clear amyloid-beta, but Alzheimer's patients' macrophages struggle with this task.
Scientists have found a way to analyze the configuration of amyloid fibers using yeast strains, providing insights into how prions interact with each other. The study reveals that prions have only two points of contact, known as the 'head' and 'tail,' which determine their interactions.
Researchers have gained a detailed understanding of the interconnected protein segments that form amyloid fibrils, a key feature in various diseases. The structure reveals a 'spine' made up of short zippers that are tightly bonded together.
The discovery of CD147 reveals a new component regulating the production of A-beta peptides, which form amyloid plaques. The study highlights the importance of understanding membrane protein structures to combat Alzheimer's research.
Researchers found that patients who mounted an immune response against beta amyloid experienced improved memory performance and reduced brain size, suggesting the removal of built-up protein. The new trial aims to stimulate an immune attack without raising brain inflammation risk.
A study found that short heparansulfate chains trigger amyloid deposits, which are associated with Alzheimer's disease. The research suggests that short segments of sugar chains may be useful in developing new drugs for the condition.
Researchers found that small soluble protein clusters called oligomers cause neurotoxicity by increasing membrane permeability. This challenges the long-held idea that insoluble fibrils are responsible for disease symptoms.
Scripps Research scientists identified that certain tissues are more susceptible to amyloid plaques due to their ability to efficiently release misfolded protein. The study found that cells secreting proteins into these tissues secrete the bad proteins most efficiently, making them a key factor in tissue selectivity.
Researchers have developed a polymer that acts as a decoy for beta amyloid proteins, attracting them away from brain cells and preventing their accumulation. This approach shows promise for slowing Alzheimer's disease progression and may lead to the development of new diagnostic tools.
Researchers at Duke University are using advanced atomic force microscopy techniques to study the interactions of individual amyloid protein molecules, which may hold key to preventing plaque formation. The goal is to develop a better understanding of amyloid aggregation and its role in neurodegenerative diseases.
A UCI research team identified beta amyloid accumulation within neurons as the trigger for Alzheimer's memory decline in mice. By clearing away excess beta amyloid, they were able to correct memory impairments. The findings have implications for developing drugs targeting beta amyloid.
A study by Mount Sinai School of Medicine found that mice fed a reduced carbohydrate diet slowed disease progression, with anti-amyloidogenic activities increased and plaque development prevented. The findings provide a possible mechanism for caloric reduction to prevent Alzheimer's disease.
UT Southwestern researchers developed a gene-based vaccine to stimulate immune systems against amyloid protein, reducing plaque buildup and cognitive loss in mice. The study aims to create a safe and effective Alzheimer's vaccine that can prevent or slow disease progression.
Researchers have identified a new species of amyloid β-peptide, Aβ46, which is 46 amino acids long and produced by γ-secretase at a novel cleavage site. This discovery may provide new insights into the mechanism of Alzheimer's disease and open up avenues for treatment and prevention.
A UK researcher has made significant breakthroughs in understanding the mechanisms of Alzheimer's disease. The study found that methionine in the human amyloid beta peptide is a key contributor to the disease, causing damage to neurons and decreased cell viability.
Apolipoprotein E is responsible for converting harmless amyloid-beta protein into toxic filamentous amyloid, a major hallmark of Alzheimer's disease. Mice with the gene showed memory deficits only when it was present.
Researchers developed a new approach to block protein interactions, leading to reduced amyloid aggregation and toxicity in Alzheimer's disease. The 'Trojan horse' technique uses small molecules to target protein chaperones, preventing the formation of toxic aggregates.
A new anti-cholesterol drug, CP-113,818, has shown promise in treating Alzheimer's disease by reducing amyloid plaque accumulation and improving learning and memory in mice. Treatment with the drug resulted in a significant reduction of cholesterol storage in the brain, as well as improved performance on cognitive tests.